Inspiremd Inc (NSPR) Stock Price, Quote & News

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 776 6804

Website: www.inspiremd.com

Address:

6303 Waterford District Drive, Suite 215, Miami, United States

Ronnie5isAlive Jun. 15 at 9:13 PM

$NSPR owning this stock feels like I bought lotto scratchers.

0 · Reply

PenkeTrading Jun. 14 at 4:11 AM

I found you a Falling Three Methods Candle Pattern on the daily chart of InspireMD Inc. $NSPR #InspireMD #FallingThreeMethods #NASDAQ

0 · Reply

Jackedtothetits42 Jun. 13 at 6:22 PM

$NSPR it’s just a matter of time

1 · Reply

Threeways Jun. 13 at 5:55 PM

$NSPR its crazy this stock has zero FOMO. Guess we can bag hold for a year when they finally start making profit. Unless Marvin keeps spending more

1 · Reply

woodstockery Jun. 13 at 4:57 PM

$NSPR

0 · Reply

BearTamerTrading Jun. 13 at 3:42 PM

$NSPR I’m in here here like swimwear. Let’s see how the market reacts.

0 · Reply

QuiverQuant Jun. 13 at 2:57 PM

InspireMD, Inc. Secures CE Mark Approval for CGuard® Prime EPS Carotid Stent System Read more on $NSPR: https://www.quiverquant.com/news/InspireMD%2C+Inc.+Secures+CE+Mark+Approval+for+CGuard%C2%AE+Prime+EPS+Carotid+Stent+System

0 · Reply

GiveHerTheDD Jun. 13 at 2:32 PM

$NSPR CGuard Prime got CE Mark designation today. There should be record revenues for this quarter as they were previously holding sales in EU until this was achieved. Why is it trading poorly off such great news? Whooooo knows.

1 · Reply

woodstockery Jun. 13 at 12:22 AM

$NSPR medtech presentation tomorrow

0 · Reply

LoyalShark Jun. 12 at 1:13 PM

$NSPR Nothing with these guys ever changes.

1 · Reply

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

May 9, 2025, 12:07 PM EDT - 5 weeks ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:00 AM EDT - 5 weeks ago

InspireMD Reports First Quarter 2025 Financial Results

Apr 30, 2025, 9:00 AM EDT - 6 weeks ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 25, 2025, 9:00 AM EDT - 7 weeks ago

InspireMD to Announce First Quarter 2025 Financial Results

Apr 8, 2025, 9:00 AM EDT - 2 months ago

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 26, 2025, 9:00 AM EDT - 2 months ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 12, 2025, 1:53 PM EDT - 3 months ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 7:00 AM EDT - 3 months ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 3 months ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 7:00 AM EST - 4 months ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Dec 9, 2024, 7:00 AM EST - 6 months ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Nov 25, 2024, 4:05 PM EST - 7 months ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 12, 2024, 10:20 AM EST - 7 months ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Oct 15, 2024, 7:00 AM EDT - 8 months ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 8 months ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 9 months ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Aug 9, 2024, 8:58 AM EDT - 11 months ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 8:09 AM EDT - 11 months ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:00 AM EDT - 11 months ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Jul 30, 2024, 7:00 AM EDT - 11 months ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

May 28, 2024, 8:53 AM EDT - 1 year ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 14, 2024, 10:50 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

Apr 3, 2024, 8:59 AM EDT - 1 year ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 6, 2024, 11:30 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:00 AM EST - 1 year ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 1 year ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Feb 12, 2024, 7:00 AM EST - 1 year ago

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Jan 31, 2024, 7:00 AM EST - 1 year ago

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

Jan 3, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Dec 20, 2023, 7:00 AM EST - 1 year ago

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Nov 27, 2023, 7:00 AM EST - 1 year ago

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Nov 6, 2023, 11:09 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 7:00 AM EST - 1 year ago

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 2, 2023, 8:00 AM EDT - 1 year ago

InspireMD to Participate in Upcoming November Investor Conferences

Nov 1, 2023, 2:19 PM EDT - 1 year ago

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

Oct 30, 2023, 9:21 AM EDT - 1 year ago

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

Oct 12, 2023, 7:00 AM EDT - 1 year ago

InspireMD Supports CMS' Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients

Oct 3, 2023, 7:00 AM EDT - 1 year ago

InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives

Aug 31, 2023, 8:00 AM EDT - 1 year ago

InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23

Aug 8, 2023, 11:18 AM EDT - 2 years ago

InspireMD Inc. (NSPR) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 7:00 AM EDT - 2 years ago

InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 25, 2023, 8:00 AM EDT - 2 years ago

InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th

Jun 26, 2023, 8:00 AM EDT - 2 years ago

InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial

May 18, 2023, 8:00 AM EDT - 2 years ago

InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

May 16, 2023, 11:24 AM EDT - 2 years ago

InspireMD, Inc. (NSPR) Q1 2023 Earnings Call Transcript

May 16, 2023, 7:00 AM EDT - 2 years ago

InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update

Ronnie5isAlive Jun. 15 at 9:13 PM

$NSPR owning this stock feels like I bought lotto scratchers.

0 · Reply

PenkeTrading Jun. 14 at 4:11 AM

I found you a Falling Three Methods Candle Pattern on the daily chart of InspireMD Inc. $NSPR #InspireMD #FallingThreeMethods #NASDAQ

0 · Reply

Jackedtothetits42 Jun. 13 at 6:22 PM

$NSPR it’s just a matter of time

1 · Reply

Threeways Jun. 13 at 5:55 PM

$NSPR its crazy this stock has zero FOMO. Guess we can bag hold for a year when they finally start making profit. Unless Marvin keeps spending more

1 · Reply

woodstockery Jun. 13 at 4:57 PM

$NSPR

0 · Reply

BearTamerTrading Jun. 13 at 3:42 PM

$NSPR I’m in here here like swimwear. Let’s see how the market reacts.

0 · Reply

QuiverQuant Jun. 13 at 2:57 PM

0 · Reply

GiveHerTheDD Jun. 13 at 2:32 PM

1 · Reply

woodstockery Jun. 13 at 12:22 AM

$NSPR medtech presentation tomorrow

0 · Reply

LoyalShark Jun. 12 at 1:13 PM

$NSPR Nothing with these guys ever changes.

1 · Reply

BioBuddha Jun. 11 at 7:47 PM

$NSPR the stock is being held around 2.5 means somebody has an obligatory position around 2.5. Let it clear. The product is good. Eventually this will do well. I have waited long time - what’s another few quarters

2 · Reply

JBinLB Jun. 11 at 1:42 PM

$NSPR money in the mattress has a better 5 year ROI

2 · Reply

LoyalShark Jun. 9 at 3:23 PM

$BMXI $VGZ $NSPR I loved $BMXI at .05. Love it a thousand times more at .013 !!! They had a seller blow out of 30 million shares -- dumped straight into the market😂. What a freaken idiot. Known seller just blowing up everyone as a source of pride. Those shares are not diperedispersedsed in thete market. BMXI The company is very real. The cash they are generating is green. They make NET more in a quart er than the entire marketcap. There is a reason it is at this level. Those reasons are pretty much the past. BMXI dispersedCheap. INCREDIBLY cheap.

0 · Reply

HOBOWITHASHOTGUN Jun. 9 at 2:20 PM

$NSPR AMAZING Liquidity! WOW! Oh wait, I was watching $APLD - Sorry.

1 · Reply

Ronnie5isAlive Jun. 9 at 1:51 PM

$NSPR

0 · Reply

Thespectator Jun. 7 at 12:03 AM

$NSPR I told you guys through the toxic financing deal they secured last year they no longer care about retail participation, timelines etc, they’ll take as long as needed to bleed you dry

0 · Reply

jensen146 Jun. 6 at 7:31 PM

$NSPR Ask 100 people what the word imminent means and I am sure very few would say a few weeks. Ask 100 people what they think of giving the new CFO 400K shares very few might say good idea. Look how he has moved the needle after the announcement, not. Probably his first official act will be to announce a secondary, and dilute us further.

0 · Reply

Threeways Jun. 6 at 5:04 PM

$NSPR it seems like an abundance of shares get sold at $2.50. The only logical reason is dip shyt Marvin is selling more shares through the ATM keeping the price down. Asshat always does us dirty. If he’d stop lighting our money on fire we could see movement

1 · Reply

abdolfos Jun. 6 at 3:00 PM

$NSPR 1200 shares traded...hold your seatbelts...FOMO is happening!

0 · Reply

zigsfrd Jun. 5 at 10:29 PM

$NSPR Good stock to sell at 2.60 and buy at 2.50. Can make a dime either way!

0 · Reply

futuregssummeranalyst Jun. 5 at 9:40 PM

$NSPR fuck this stock

0 · Reply

abdolfos Jun. 5 at 8:08 PM

$NSPR these guys love to close the stock at 2.5$...they are fucking in love with 2.5$...it is like a magnet

0 · Reply

Market Cap	71.07M
Revenue (ttm)	7.01M
Net Income (ttm)	-32.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-456.63%
Debt to Equity Ratio	0.00

Volume	126,400
Avg Vol	46,140
Day's Range	N/A - N/A
Shares Out	30.64M
Stochastic %K	17%
Beta	0.59
Analysts	Strong Sell
Price Target	$4.50